Bristol Myers Squibb (CELG-RI) Payables (2009 - 2026)

Bristol Myers Squibb has disclosed Payables across 18 years of filings, most recently posting $4.2 billion for Q1 2026.

• In Q1 2026, Payables rose 5.8% year-over-year to $4.2 billion; the TTM figure through Mar 2026 stood at $4.2 billion (up 5.8% YoY), while the FY2025 annual figure was $3.6 billion, down 0.75% from the prior year.
• Payables climbed to $4.2 billion in Q1 2026, from $3.6 billion in the prior quarter.
• Over the last five years, Payables for CELG-RI reached as high as $5.4 billion in Q2 2025 and fell as low as $2.6 billion in Q3 2022.
• The 5-year median for Payables is $3.5 billion (2024), against an average of $3.5 billion.
• Annual changes were most pronounced in 2022 — Payables dropped 20.14% — and 2025, when it jumped 44.68%.
• A 5-year view of Payables shows it stood at $3.0 billion in 2022, then gained by 7.2% to $3.3 billion in 2023, then climbed by 10.52% to $3.6 billion in 2024, then decreased by 0.75% to $3.6 billion in 2025, then increased by 18.43% to $4.2 billion in 2026.
• According to Business Quant data, Payables over the past three periods registered $4.2 billion, $3.6 billion, and $4.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.